Dose-finding study of KP-607 in patients with onychomycosis (PhaseII)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225203

Enrollment

Registered

2020-05-25

Start date

2020-06-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Onychomycosis

Interventions

investigational material(s) Generic name etc : 10% KP-607, 5% KP-607 INN of investigational material : - Therapeutic category code : 265 Anti-dermoinfectives Dosage and Administration for Investigatio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Japanese subjects The subjects diagnosed with onychomycosis Presence of 20-50% of the area of the target nail being clinically affected (as determined by the Investigator)

Exclusion criteria

Exclusion criteria: Patients who have received corticosteroids,immunosuppressants, or antifungals drugs within a certain period of time before screening period

Design outcomes

Primary

Measure	Time frame
safety efficacy Safety, Efficacy	—

Secondary

Measure	Time frame
pharmacokinetics KP-607 and its metabolites concentrations when applied repeatedly to toenails in patients with onychomycosis	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026